ClinicalTrials.gg
CompletedNCT02197806Updated Dec 3, 2015Results posted

Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia

A Phase 2 interventional study of AGN-199201 and AGN-190584 in Presbyopia, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 40 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-12-03.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Presbyopia with a site in United States — 8 open to participants now, 10 under way, 1 of them phase 3. Presbyopia · United States.

Enrollment
67th of 120
65 · median 75
Started
2014
with 5 others
Phase 2
15 of 131
none open now
Registered
18th of 131
by date
Lead sponsor
7 of 131
Allergan

Among the 131 studies in Presbyopia with a site in United States, this one is the 67th largest by enrollment of the 120 interventional ones that give a count, is one of 6 that started in 2014, is one of 15 in phase 2, and was the 18th registered.

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

Browse Presbyopia studies →

Open to participants now

8 of the 131 studies in Presbyopia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Presbyopia studies recruiting now, 7 (39%) set no upper age limit and 9 (50%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 40 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Presbyopia with a site in United States, or all of them as a file.
02

Study summary

A study to evaluate the safety and efficacy of AGN-199201 alone, AGN-190584 alone and concurrent use of AGN-199201 and AGN-190584 in patients with presbyopia (inability to focus for near vision).

03

Conditions studied

  • Presbyopia

Browse trials for

04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Presbyopia in each eye that impacts daily activities.

Exclusion criteria

Exclusion Criteria:

  • Use of any topical ophthalmic medications, including artificial tears
  • Contact lens use in either eye within 14 days or planned use during the study
  • History of eye surgery
  • Diagnosis of any type of glaucoma or ocular hypertension
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    AGN-199201

    1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.

    Drug: AGN-199201 · Drug: AGN-199201 Vehicle

  • Experimental
    AGN-190584

    1 drop of AGN-190584 ophthalmic solution followed by 1 drop of AGN-199201 vehicle in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.

    Drug: AGN-190584 · Drug: AGN-199201 Vehicle

  • Experimental
    AGN-199201 + AGN-190584 in One Eye

    1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in the non-dominant eye and 2 drops of AGN-199201 vehicle in the dominant eye, once and twice daily for 3 days each.

    Drug: AGN-199201 · Drug: AGN-190584 · Drug: AGN-199201 Vehicle

  • Experimental
    AGN-199201 + AGN-190584 in Both Eyes

    1 drop of AGN-199201 ophthalmic solution followed by 1 drop of AGN-190584 ophthalmic solution in both eyes, once and twice daily for 3 days each.

    Drug: AGN-199201 · Drug: AGN-190584

Interventions

  • 1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.

  • 1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.

  • DrugAGN-199201 Vehicle

    1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye

    UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved. The percentages of patients with at least a 2 or more line improvement in UNVA in the non-dominant eye are presented.

    Time frame: Baseline, Day 3

07

Results

Posted Dec 3, 2015

Participant flow

Participant flow — Overall Study
MilestoneAGN-199201AGN-190584AGN-199201 + AGN-190584 in One EyeAGN-199201 + AGN-190584 in Both Eyes
Started15171617
Completed15161616
Not completed0101
Withdrew: Adverse event0101

Outcome measures

PrimaryPercentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye

UNVA is assessed without corrective lenses in the non-dominant eye. UNVA is measured using an eye chart and is reported as the number of lines read correctly. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of lines read correctly means that vision has improved. The percentages of patients with at least a 2 or more line improvement in UNVA in the non-dominant eye are presented.

Time frame:
Baseline, Day 3
Reported as:
Number · Percentage of Patients
Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye
Percentage of PatientsAGN-199201AGN-190584AGN-199201 + AGN-190584 in One EyeAGN-199201 + AGN-190584 in Both Eyes
Percentage of Participants With at Least a 2 Line Improvement From Baseline in Uncorrected Near Visual Acuity (UNVA) in the Non-Dominant Eye46.770.656.368.8

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-199201—0/15 (0%)5/15 (33.3%)
AGN-190584—0/17 (0%)4/17 (23.5%)
AGN-199201 + AGN-190584 in One Eye—0/16 (0%)8/16 (50%)
AGN-199201 + AGN-190584 in Both Eyes—0/17 (0%)5/17 (29.4%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventAGN-199201AGN-190584AGN-199201 + AGN-190584 in One EyeAGN-199201 + AGN-190584 in Both Eyes
Eyelid RetractionEye disorders4/150/171/160/17
HeadacheNervous system disorders0/150/172/163/17
Vision BlurredEye disorders0/151/172/161/17
Ocular DiscomfortEye disorders0/150/172/160/17
Punctate KeratitisEye disorders1/150/170/160/17
Upper Respiratory Tract InfectionInfections and infestations1/150/170/160/17
Conjunctival HyperaemiaEye disorders0/151/171/161/17
Lacrimation IncreasedEye disorders0/151/171/161/17
PhotophobiaEye disorders0/150/171/160/17
DiscomfortGeneral disorders0/150/171/160/17

Baseline characteristics

Age, Continuous
Age, Continuous(Years)AGN-199201AGN-190584AGN-199201 + AGN-190584 in One EyeAGN-199201 + AGN-190584 in Both EyesTotal
Mean49.9 ± 3.8849.1 ± 3.4748.7 ± 4.1649.1 ± 3.9749.2 ± 3.81
Sex: Female, Male
Sex: Female, Male(Participants)AGN-199201AGN-190584AGN-199201 + AGN-190584 in One EyeAGN-199201 + AGN-190584 in Both EyesTotal
Female131371043
Male249722
08

Study locations

1 site
  • Newport Beach, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014, a primary completion of Oct 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2014
First posted
Jul 23, 2014
Start
Jul 2014
Primary completionActual
Oct 2014
CompletionActual
Nov 2014
Results first posted
Dec 3, 2015
Last update
Dec 3, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02197806
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jul 23, 2014
Start date
Jul 2014
Primary completion
Oct 2014
Completion
Nov 2014
Results posted
Dec 3, 2015
Last update
Dec 3, 2015

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxymetazoline · AGN-190584

Start the discussion